Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans

Abstract

AbstractThe use of antisense molecules to inhibit the expression of disease-causing proteins represents a new paradigm in disease treatment. The molecular target for the antisense molecules, mRNA, is chemically and biologically well defined. This well-defined target is the same for all different possible therapeutic applications, whether the application is antiviral, anticancer, or anti-inflammatory. The specificity with which antisense molecules are capable of inhibiting gene expression, exemplified by the isozyme selectivity demonstrated by [Dean and Mckay 1994], has allowed entirely novel molecular targets to be explored for potential therapeutic applications. Thus antisense molecules have presented an opportunity to exploit a single target for multiple therapeutic indications as well as to explore the utility of inhibiting targets which traditional therapeutic agents could not specifically inhibit.KeywordsPharmacokinetic PropertyAntisense OligonucleotidePeak Plasma ConcentrationGenital WartContinuous Intravenous InfusionThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.